RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Myron G. Best(Cancer Center Amsterdam), Nik Sol(Cancer Center Amsterdam), Irsan Kooi(Cancer Center Amsterdam), Jihane Tannous(Harvard University), Bart A. Westerman(Cancer Center Amsterdam), François Rustenburg(Cancer Center Amsterdam), Pepijn Schellen(Cancer Center Amsterdam), Heleen Verschueren(Cancer Center Amsterdam), Edward P. Post(Cancer Center Amsterdam), Jan Köster(Amsterdam UMC Location University of Amsterdam), Bauke Ylstra(Cancer Center Amsterdam), Najim Ameziane(Cancer Center Amsterdam), Josephine C. Dorsman(Cancer Center Amsterdam), Egbert F. Smit(Cancer Center Amsterdam), Henk M.W. Verheul(Cancer Center Amsterdam), David P. Noske(Cancer Center Amsterdam), Jaap C. Reijneveld(Cancer Center Amsterdam), R. Jonas A. Nilsson(Cancer Center Amsterdam), Bakhos A. Tannous(Harvard University), Pieter Wesseling(Radboud University Nijmegen), Thomas Würdinger(Harvard University)
Cancer Cell
November 1, 2015
Cited by 892Open Access
Full Text

Abstract

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".


Related Papers

No related papers found

Powered by citation graph analysis